RADAR-CNS: Remote Assessment of Disease and Relapse – Central Nervous SystemA collaborative research programme exploring the potential of wearable devices to help prevent and treat depression, multiple sclerosis and epilepsy
Remote Assessment of Disease and Relapse – Central Nervous System (RADAR-CNS) is a new collaborative research programme that will explore the potential of wearable devices to help prevent and treat depression, multiple sclerosis and epilepsy.
RADAR-CNS is a major new research programme which is developing new ways of monitoring major depressive disorder, epilepsy, and multiple sclerosis using wearable devices and smartphone technology. RADAR-CNS aims to improve patients’ quality of life, and potentially to change how these and other chronic disorders are treated.
RADAR-CNS is jointly led by King’s College London and Janssen Pharmaceutica NV, funded by the Innovative Medicines Initiative (a Public Private Partnership established between the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Union) and includes 23 organisations from across Europe and the US. It brings together experts from diverse fields including clinical research, engineering, computer science, information technology, data analytics and health services.
Complete a short survey and help RADAR-CNS
Researchers on the Remote Assessment of Disease and Relapse in Central Nervous System Disorders (RADAR-CNS) project have launched a new survey to assess how people affected by epilepsy, multiple sclerosis or depression use technology.
RADAR-CNS is a major international research project.
It aims to develop new ways of measuring major depressive disorder, epilepsy and multiple sclerosis (MS) using wearable devices and smartphone technology.
RADAR-CNS focuses on depression, multiple sclerosis (MS) and epilepsy.
While the symptoms and disability experienced by individuals with each condition are different, they all have a significant effect on people’s wellbeing.
Want to get involved? RADAR-CNS is open to all.
We are especially keen to involve people affected by epilepsy, multiple sclerosis and depression, in our research.